Divarasib

Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Anika Sharma
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...